RELMADA THERAPEUTICS INC (RLMD)
US75955J4022 - Common Stock
Taking everything into account, RLMD scores 2 out of 10 in our fundamental rating. RLMD was compared to 191 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for RLMD as it has an excellent financial health rating, but there are worries on the profitability. RLMD has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year RLMD has reported negative net income.
RLMD had a negative operating cash flow in the past year.
RLMD had negative earnings in each of the past 5 years.
In the past 5 years RLMD always reported negative operating cash flow.
1.2 Ratios
RLMD has a Return On Assets of -155.21%. This is amonst the worse of the industry: RLMD underperforms 86.41% of its industry peers.
Looking at the Return On Equity, with a value of -181.60%, RLMD is doing worse than 67.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -155.21% | ||
| ROE | -181.6% | ||
| ROIC | N/A |
ROA(3y)-86.76%
ROA(5y)-96.08%
ROE(3y)-95.99%
ROE(5y)-114.43%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RLMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RLMD has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for RLMD has been increased compared to 5 years ago.
RLMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
RLMD has an Altman-Z score of -18.98. This is a bad value and indicates that RLMD is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of RLMD (-18.98) is worse than 84.78% of its industry peers.
RLMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.98 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 6.88 indicates that RLMD has no problem at all paying its short term obligations.
The Current ratio of RLMD (6.88) is better than 74.46% of its industry peers.
A Quick Ratio of 6.88 indicates that RLMD has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.88, RLMD is doing good in the industry, outperforming 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.88 | ||
| Quick Ratio | 6.88 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.45% over the past year.
EPS 1Y (TTM)25.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
RLMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.17% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y14.82%
EPS Next 2Y28.2%
EPS Next 3Y14.4%
EPS Next 5Y12.17%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RLMD. In the last year negative earnings were reported.
Also next year RLMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RLMD's earnings are expected to grow with 14.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.2%
EPS Next 3Y14.4%
5. Dividend
5.1 Amount
RLMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RELMADA THERAPEUTICS INC
NASDAQ:RLMD (1/3/2025, 8:00:02 PM)
After market: 0.46 -0.01 (-2.15%)0.4701
+0.02 (+4.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners45.95%
Inst Owner Change-4.14%
Ins Owners8.74%
Ins Owner Change20.08%
Market Cap14.18M
Analysts47.5
Price Target0.88 (87.19%)
Short Float %6.47%
Short Ratio1.69
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.95%
Min EPS beat(2)-10.12%
Max EPS beat(2)30.01%
EPS beat(4)3
Avg EPS beat(4)9.39%
Min EPS beat(4)-10.12%
Max EPS beat(4)30.01%
EPS beat(8)6
Avg EPS beat(8)8.41%
EPS beat(12)8
Avg EPS beat(12)5.95%
EPS beat(16)9
Avg EPS beat(16)0.8%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-92.78%
PT rev (3m)-93.07%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.89%
EPS NY rev (1m)-1.09%
EPS NY rev (3m)-6.85%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.3 | ||
| P/tB | 0.3 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.87
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.76
OCFYN/A
SpS0
BVpS1.58
TBVpS1.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -155.21% | ||
| ROE | -181.6% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-86.76%
ROA(5y)-96.08%
ROE(3y)-95.99%
ROE(5y)-114.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.88 | ||
| Quick Ratio | 6.88 | ||
| Altman-Z | -18.98 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.37%
EPS Next Y14.82%
EPS Next 2Y28.2%
EPS Next 3Y14.4%
EPS Next 5Y12.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.57%
EBIT Next 3Y-6.52%
EBIT Next 5YN/A
FCF growth 1Y49.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.61%
OCF growth 3YN/A
OCF growth 5YN/A